Allogene Therapeutics Inc (ALLO) concluded trading on Wednesday at a closing price of $1.66, with 7.01 million shares of worth about $11.64 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -9.78% during that period and on July 23, 2025 the price saw a gain of about 16.90%. Currently the company’s common shares owned by public are about 218.60M shares, out of which, 149.51M shares are available for trading.
Stock saw a price change of 34.96% in past 5 days and over the past one month there was a price change of 36.07%. Year-to-date (YTD), ALLO shares are showing a performance of -41.34% which decreased to -22.07% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.86 but also hit the highest price of $3.78 during that period. The average intraday trading volume for Allogene Therapeutics Inc shares is 3.27 million. The stock is currently trading 32.38% above its 20-day simple moving average (SMA20), while that difference is up 33.97% for SMA50 and it goes to -9.89% lower than SMA200.
Allogene Therapeutics Inc (NASDAQ: ALLO) currently have 218.60M outstanding shares and institutions hold larger chunk of about 67.48% of that.
The stock has a current market capitalization of $363.10M and its 3Y-monthly beta is at 0.36. It has posted earnings per share of -$1.23 in the same period. It has Quick Ratio of 9.71 while making debt-to-equity ratio of 0.23. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALLO, volatility over the week remained 9.50% while standing at 7.55% over the month.
Analysts are in expectations that Allogene Therapeutics Inc (ALLO) stock would likely to be making an EPS of -0.26 in the current quarter, while forecast for next quarter EPS is -0.24 and it is -1.01 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.3 which is -0.21 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.32 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 23.59% while it is estimated to increase by 2.30% in next year. EPS is likely to grow at an annualized rate of 8.47% for next 5-years, compared to annual growth of 6.26% made by the stock over the past 5-years.
Coverage by Citizens JMP stated Allogene Therapeutics Inc (ALLO) stock as a Mkt outperform in their note to investors on March 14, 2025, suggesting a price target of $5 for the stock. On August 08, 2024, Oppenheimer Resumed their recommendations, while on May 31, 2024, Piper Sandler Initiated their ratings for the stock with a price target of $11. Stock get a Mkt perform rating from JMP Securities on January 05, 2024.
